# Clinical Trial of TQB3002 in Patients With Advanced Cancers

> **NCT06662760** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQB3002 Tablets

## Key facts

- **NCT ID:** NCT06662760
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2025-11
- **Final completion:** 2026-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662760, "Clinical Trial of TQB3002 in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06662760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*